EMA Recommends Extension of Therapeutic Indications for Fosaprepitant

It is indicated for prevention of nausea and vomiting associated with highly and moderately emetogenic chemotherapy in adult and paediatric patients

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply